HealthStream Announces Third Quarter 2020 Results
Third Quarter 2020
-
Revenues of
$60.9 million in the third quarter of 2020, down 3% from$62.5 million in the third quarter of 2019. -
Operating income of
$3.1 million in the third quarter of 2020, down 16% from$3.7 million in the third quarter of 2019. -
Income from continuing operations of
$2.6 million in the third quarter of 2020, down 24% from$3.5 million in the third quarter of 2019. -
Earnings per share (EPS) from continuing operations of
$0.08 per share (diluted) in the third quarter of 2020 down from$0.11 per share (diluted) in the third quarter of 2019. -
Adjusted EBITDA1 from continuing operations of
$11.1 million in the third quarter of 2020, down 3% from$11.5 million in the third quarter of 2019.
Fourth Quarter 2020 Event
-
On
October 12, 2020 , we acquiredShiftWizard, Inc. , which provides a SaaS-based solution that integrates key workforce management capabilities, including scheduling, productivity, and forecasting.
Financial Results:
Third Quarter 2020 Compared to Third Quarter 2019
Revenues for the third quarter of 2020 decreased by
Revenues from our Workforce Solutions segment were
1 Adjusted EBITDA from continuing operations is a non-GAAP financial measure. A reconciliation of adjusted EBITDA from continuing operations to income from continuing operations and disclosure regarding why we believe adjusted EBITDA from continuing operations provides useful information to investors is included later in this release. |
Revenues from our Provider Solutions segment were
Operating income was
Income from continuing operations was
Adjusted EBITDA from continuing operations was
At
Year-to-Date 2020 Compared to Year-to-Date 2019
For the first nine months of 2020, revenues were
Other Business Updates
At
On
Fourth Quarter 2020 Event
On
Financial Outlook for 2020
The Company continues to believe that the extent, timing, and duration of COVID-19’s negative impact on its operating results and financial condition will be driven by many factors, including the length and severity of the COVID-19 pandemic and the impact of the pandemic on economic activity, particularly with respect to healthcare organizations. As a result of the unpredictable and evolving environment related to the COVID-19 pandemic, the Company is not providing 2020 guidance in this earnings release.
“Having completed our acquisition of ShiftWizard in October, we are pleased to welcome ShiftWizard customers and employees to HealthStream,” said
A conference call with
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA from continuing operations and adjusted EBITDA, both of which are non-GAAP financial measures used by management in analyzing the Company’s financial results and ongoing operational performance.
In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, and the de-recognition of non-cash royalty expense resulting from our resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items. Management also believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the results of operations of the PX business that we no longer own and the gain on sale in connection with the sale of such business in
These non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review the reconciliations of our GAAP to non-GAAP financial measures, which are set forth below in this release.
About
Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenues, net |
|
$ |
60,883 |
|
|
$ |
62,450 |
|
|
$ |
183,008 |
|
|
$ |
191,417 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues (excluding depreciation and amortization) |
|
|
23,302 |
|
|
|
25,348 |
|
|
|
66,596 |
|
|
|
79,015 |
|
Product development |
|
|
8,192 |
|
|
|
7,195 |
|
|
|
23,491 |
|
|
|
21,763 |
|
Sales and marketing |
|
|
8,863 |
|
|
|
9,003 |
|
|
|
26,286 |
|
|
|
28,343 |
|
Other general and administrative expenses |
|
|
9,986 |
|
|
|
10,007 |
|
|
|
29,949 |
|
|
|
30,283 |
|
Depreciation and amortization |
|
|
7,406 |
|
|
|
7,149 |
|
|
|
22,005 |
|
|
|
20,629 |
|
Total operating costs and expenses |
|
|
57,749 |
|
|
|
58,702 |
|
|
|
168,327 |
|
|
|
180,033 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
3,134 |
|
|
|
3,748 |
|
|
|
14,681 |
|
|
|
11,384 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income, net |
|
|
100 |
|
|
|
853 |
|
|
|
2,006 |
|
|
|
2,528 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision |
|
|
3,234 |
|
|
|
4,601 |
|
|
|
16,687 |
|
|
|
13,912 |
|
Income tax provision |
|
|
600 |
|
|
|
1,140 |
|
|
|
3,519 |
|
|
|
3,270 |
|
Income from continuing operations |
|
|
2,634 |
|
|
|
3,461 |
|
|
|
13,168 |
|
|
|
10,642 |
|
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of discontinued operations |
|
|
— |
|
|
|
340 |
|
|
|
— |
|
|
|
1,960 |
|
Income tax provision |
|
|
— |
|
|
|
89 |
|
|
|
— |
|
|
|
515 |
|
Income from discontinued operations |
|
|
— |
|
|
|
251 |
|
|
|
— |
|
|
|
1,445 |
|
Net income |
|
$ |
2,634 |
|
|
$ |
3,712 |
|
|
$ |
13,168 |
|
|
$ |
12,087 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share – basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.08 |
|
|
$ |
0.11 |
|
|
$ |
0.41 |
|
|
$ |
0.33 |
|
Discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.04 |
|
Net income per share - basic |
|
$ |
0.08 |
|
|
$ |
0.11 |
|
|
$ |
0.41 |
|
|
$ |
0.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share - diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.08 |
|
|
$ |
0.11 |
|
|
$ |
0.41 |
|
|
$ |
0.33 |
|
Discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.04 |
|
Net income per share - diluted |
|
$ |
0.08 |
|
|
$ |
0.11 |
|
|
$ |
0.41 |
|
|
$ |
0.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
31,955 |
|
|
|
32,376 |
|
|
|
32,095 |
|
|
|
32,369 |
|
Diluted |
|
|
31,981 |
|
|
|
32,437 |
|
|
|
32,121 |
|
|
|
32,416 |
|
Condensed Consolidated Balance Sheets (In thousands) (Unaudited) |
||||||||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
|
2020 |
|
|
2019 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
107,007 |
|
|
$ |
131,538 |
|
Marketable securities |
|
|
42,666 |
|
|
|
41,328 |
|
Accounts and unbilled receivables, net |
|
|
30,305 |
|
|
|
30,376 |
|
Prepaid and other current assets |
|
|
19,119 |
|
|
|
21,330 |
|
Total current assets |
|
|
199,097 |
|
|
|
224,572 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
24,679 |
|
|
|
21,445 |
|
Property and equipment, net |
|
|
21,793 |
|
|
|
26,065 |
|
Operating lease right of use assets, net |
|
|
27,707 |
|
|
|
29,615 |
|
|
|
|
177,773 |
|
|
|
162,277 |
|
Deferred tax assets |
|
|
269 |
|
|
|
269 |
|
Deferred commissions |
|
|
17,783 |
|
|
|
17,645 |
|
Other assets |
|
|
7,456 |
|
|
|
7,656 |
|
Total assets |
|
$ |
476,557 |
|
|
$ |
489,544 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
32,404 |
|
|
$ |
39,674 |
|
Deferred revenue |
|
|
62,610 |
|
|
|
65,511 |
|
Total current liabilities |
|
|
95,014 |
|
|
|
105,185 |
|
Deferred tax liabilities |
|
|
13,394 |
|
|
|
13,183 |
|
Deferred revenue, non-current |
|
|
1,751 |
|
|
|
1,918 |
|
Operating lease liability, noncurrent |
|
|
28,665 |
|
|
|
30,733 |
|
Other long-term liabilities |
|
|
1,468 |
|
|
|
357 |
|
Total liabilities |
|
|
140,292 |
|
|
|
151,376 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
274,905 |
|
|
|
290,021 |
|
Accumulated other comprehensive income |
|
|
6 |
|
|
|
4 |
|
Retained earnings |
|
|
61,354 |
|
|
|
48,143 |
|
Total shareholders’ equity |
|
|
336,265 |
|
|
|
338,168 |
|
Total liabilities and shareholders' equity |
|
$ |
476,557 |
|
|
$ |
489,544 |
|
Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
||||||||
|
|
|
|
|||||
|
|
Nine Months Ended |
|
|||||
|
|
|
|
|
|
|
||
|
|
2020 |
|
|
2019 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
13,168 |
|
|
$ |
12,087 |
|
Income from discontinued operations |
|
|
— |
|
|
|
(1,445 |
) |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
22,005 |
|
|
|
20,629 |
|
Stock based compensation |
|
|
1,665 |
|
|
|
3,643 |
|
Amortization of deferred commissions |
|
|
6,555 |
|
|
|
6,269 |
|
Deferred income taxes |
|
|
2,330 |
|
|
|
1,803 |
|
Provision for doubtful accounts |
|
|
160 |
|
|
|
99 |
|
Loss (gain) on equity method investments |
|
|
8 |
|
|
|
(87 |
) |
Non-cash royalty expense |
|
|
(3,440 |
) |
|
|
— |
|
Change in fair value of non-marketable equity investments |
|
|
(1,181 |
) |
|
|
— |
|
Other |
|
|
321 |
|
|
|
(101 |
) |
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
(9 |
) |
|
|
13,624 |
|
Prepaid and other assets |
|
|
(4,019 |
) |
|
|
108 |
|
Accounts payable, accrued and other liabilities |
|
|
(3,668 |
) |
|
|
(1,629 |
) |
Deferred revenue |
|
|
(3,142 |
) |
|
|
(2,453 |
) |
Net cash provided by operating activities |
|
|
30,753 |
|
|
|
52,547 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(21,449 |
) |
|
|
(18,018 |
) |
Proceeds from sale of discontinued operations |
|
|
— |
|
|
|
6,035 |
|
Changes in marketable securities |
|
|
(1,656 |
) |
|
|
(4,105 |
) |
Proceeds from sale of fixed assets |
|
|
— |
|
|
|
13 |
|
Payments to acquire non-marketable equity investments |
|
|
(1,257 |
) |
|
|
(3,342 |
) |
Purchases of property and equipment |
|
|
(1,734 |
) |
|
|
(21,451 |
) |
Payments associated with capitalized software development |
|
|
(12,366 |
) |
|
|
(11,179 |
) |
Net cash used in investing activities |
|
|
(38,462 |
) |
|
|
(52,047 |
) |
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
— |
|
|
|
214 |
|
Taxes paid related to net settlement of equity awards |
|
|
(429 |
) |
|
|
(1,030 |
) |
Payment of earn-outs related to prior acquisitions |
|
|
— |
|
|
|
(38 |
) |
Repurchases of common stock |
|
|
(16,352 |
) |
|
|
— |
|
Payment of cash dividends |
|
|
(40 |
) |
|
|
(53 |
) |
Net cash used in financing activities |
|
|
(16,821 |
) |
|
|
(907 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(1 |
) |
|
|
— |
|
Net decrease in cash and cash equivalents |
|
|
(24,531 |
) |
|
|
(407 |
) |
Cash and cash equivalents at beginning of period |
|
|
131,538 |
|
|
|
134,321 |
|
Cash and cash equivalents at end of period |
|
$ |
107,007 |
|
|
$ |
133,914 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) (In thousands) (Unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
GAAP income from continuing operations |
|
$ |
2,634 |
|
|
$ |
3,461 |
|
|
$ |
13,168 |
|
|
$ |
10,642 |
|
Interest income |
|
|
(88 |
) |
|
|
(864 |
) |
|
|
(919 |
) |
|
|
(2,538 |
) |
Interest expense |
|
|
26 |
|
|
|
26 |
|
|
|
76 |
|
|
|
77 |
|
Income tax provision |
|
|
600 |
|
|
|
1,140 |
|
|
|
3,519 |
|
|
|
3,270 |
|
Stock based compensation expense |
|
|
557 |
|
|
|
569 |
|
|
|
1,665 |
|
|
|
3,643 |
|
Depreciation and amortization |
|
|
7,406 |
|
|
|
7,149 |
|
|
|
22,005 |
|
|
|
20,629 |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
— |
|
|
|
(1,181 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
— |
|
|
|
(3,440 |
) |
|
|
— |
|
Adjusted EBITDA from continuing operations |
|
$ |
11,135 |
|
|
$ |
11,481 |
|
|
$ |
34,893 |
|
|
$ |
35,723 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net income |
|
$ |
2,634 |
|
|
$ |
3,712 |
|
|
$ |
13,168 |
|
|
$ |
12,087 |
|
Interest income |
|
|
(88 |
) |
|
|
(864 |
) |
|
|
(919 |
) |
|
|
(2,538 |
) |
Interest expense |
|
|
26 |
|
|
|
26 |
|
|
|
76 |
|
|
|
77 |
|
Income tax provision |
|
|
600 |
|
|
|
1,229 |
|
|
|
3,519 |
|
|
|
3,785 |
|
Stock based compensation expense |
|
|
557 |
|
|
|
569 |
|
|
|
1,665 |
|
|
|
3,643 |
|
Depreciation and amortization |
|
|
7,406 |
|
|
|
7,149 |
|
|
|
22,005 |
|
|
|
20,629 |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
— |
|
|
|
(1,181 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
— |
|
|
|
(3,440 |
) |
|
|
— |
|
Adjusted EBITDA |
|
$ |
11,135 |
|
|
$ |
11,821 |
|
|
$ |
34,893 |
|
|
$ |
37,683 |
|
(1) This press release contains certain non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA from continuing operations, which are used by management in analyzing its financial results and ongoing operational performance.
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2020 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005708/en/
Chief Financial Officer
(615) 301-3182
ir@healthstream.com
Media:
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com
Source: